Clinical trials: B-cell Leukemia
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients.
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell
- Trial name
- NCT00849147
- Testing
- Haploidentical Bone Marrow Transplantation, GVHD prophylaxis
- Where
- 17 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Leukemia, Lymphocytyc
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Background: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are types of blood or lymph node cancers that mostly affect the elderly.
- Conditions
- Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
- Trial name
- NCT01500733
- Testing
- PCI 32765
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well a dose adjusted regimen consisting of etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) works in combination with ofatumumab or rituximab in…
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT02199184
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Ibrutinib is currently FDA approved and commercially available for the treatment of CLL. However, some researchers think the approved dose may be unnecessarily high.
- Trial name
- NCT02801578
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Leukemia
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lenalidomide (Revlimid®) can help to control CLL in patients who have already received standard therapy. The safety of lenalidomide will also be studied.
- Trial name
- NCT00267059
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin Lymphoma
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and…
- Trial name
- BIANCA (NCT03610724)
- Testing
- Tisagenlecleucel, lymphodepleting chemotherapy, Bridging Therapy
- Where
- 26 sites in United States, Australia and 12 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large…
- Trial name
- NCT01030536
- Testing
- CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg
- Where
- 8 sites in United States, Poland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Glioblastoma Multiforme
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
- Trial name
- NCT02586857
- Testing
- ACP-196
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Acerta Pharma BV
Chronic Lymphocytic Leukemia
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
The purpose of this study was to provide the opportunity to the participants who progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive ublituximab (TG-1101) treatment in combination with…
- Trial name
- NCT02656303
- Testing
- Ublituximab, Umbralisib
- Where
- 87 sites in United States, Italy and 2 more
- Volunteers
- 116 people
- Sponsor
- TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
The investigators' hypothesis is that treatment of CLL with an alternating daily dosing schedule of thalidomide and lenalidomide may result in better tolerability by decreasing each agent's individual toxicities, while preserving…
- Trial name
- ThRiL (NCT01125176)
- Testing
- thalidomide, lenalidomide, rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Hepatitis, Safety and Tolerability
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened.
- Trial name
- NCT03685708
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
The main objective of this study is to determine the progression free survival of umbralisib in participants who were intolerant to prior BTK (Bruton Tyrosine Kinase) inhibitors (ibrutinib, ACP-196, other) or prior PI3K-delta…
- Trial name
- NCT02742090
- Testing
- Umbralisib
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- TG Therapeutics, Inc.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Bridalveil (NCT01732926)
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 144 sites in United States, Australia and 13 more
- Volunteers
- 475 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
The purpose of the study is to determine whether ibrutinib in combination with GA101 - Obinutuzumab might be useful for the treatment of CLL.
- Trial name
- NCT02315768
- Testing
- GA101, Ibrutinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
Chronic Lymphocytic Leukemia
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The goal of this clinical research study is to learn if ofatumumab can help to control CLL/SLL that has not yet been treated. The safety of this drug will also be studied.
- Trial name
- NCT01243190
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with…
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
- Trial name
- NCT02883049
- Testing
- Clofarabine, Cyclophosphamide, Cytarabine
- Where
- 239 sites in United States, Australia and 5 more
- Volunteers
- 5,949 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
This is a pilot study, assessing the feasibility, safety and toxicity of an mTOR (mammalian target of Rapamycin) inhibitor (MTI), rapamycin, when administered with HyperCVAD (Hyperfractionated Cyclophosphamide, Vincristine…
- Conditions
- Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Lymphoblastic Lymphoma
- Trial name
- NCT01184885
- Testing
- Hyper-CVAD, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab…
- Trial name
- NCT01980888
- Testing
- Idelalisib, Bendamustine, Rituximab
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 311 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way.
- Trial name
- NCT01173679
- Testing
- dasatinib, Rituximab, fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital